Navigation Links
Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:6/19/2008

ttp://www.t-r-co.com" target="_new">http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that new distribution agreements or other commercialization efforts will effectively accelerate InnerCool's patient temperature modulation business, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
10. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ell Report Identifies SPINK1 as a New Biomarker fo...pendia Bioscience, Inc.,the leading provider of ca...unced the central role of their flagship product O... SPINK1 as a key new therapeutic target and,biomar...rowing compendium of nearly 26,000 gene,expression...
...publication on utility of PRDT,s prion reduction t...utzfeldt-Jakob Disease ("vCJD") from ...ing lunchtime Symposium at meeting to discuss prio... product quality., MONTREAL, Canada and CAMBRIDGE... ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic"...
... Iris Recognition Algorithm Detects and Compensate...ctions, VILNIUS, Lithuania, June 10 Neurotechnol...ecognition technology to the,company,s suite of bi...elopment products. VeriEye SDK features an advance...and compensates for partial obstructions,irregular...
Other Biology Technology:Oncomine(TM) Again Key to Prostate Cancer Discovery 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How nutrition affects healthy aging 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 1DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 2Exposure to Holocaust May Have Raised Cancer Risks 60111 1Exposure to Holocaust May Have Raised Cancer Risks 60111 2Heart Disease Gender Gap Narrows 60108 1Heart Disease Gender Gap Narrows 60108 2Heart Disease Gender Gap Narrows 60108 3
...en peroxide, the same mild acid that many people u...d abrasions, is also produced by the body to keep ...versity School of Medicine have solved how part of...January 3 issue of Nature, a team led by W. Todd L...hot of how two proteins produced by cells interact...
...ions, including the National Academy of Sciences, ...l Science Teachers Association, is calling on the ...e promotion of science education, including evolut...ary 2008 issue of The FASEB Journal, the introduct...igent design, into science education will undermin...
...ay be more than a breath freshener it could spot ...Hopkins Kimmel Cancer Center. Their new study of ...mon to the disease holds promise for screening tho...ol drinkers., Lead investigator Joseph Califano, M...d and neck cancer patients and 527 individuals wit...
Other Biology News:Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2'Swish-and-spit' test accurate for cancer 2
...cessory lessens the expensive task of validating m... mass spectrometers. It converts the unprocessed d...quadrupole mass spectrometers into analog format a...ory information management (LIMS) systems for proc...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...tide Kit, designed for use with Ciphergens Protein... peptides more straightforward and faster than eve...cations - Monitor beta-amyloid expression after dr...ls with disease progression - Evaluate mechanisms ...
Biology Products: